Related Experiment Video
Updated: Mar 11, 2026
03:45
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
4.3K
[Takotsubo cardiomyopathy: current evidence from observational studies and pathophysiological background]
Francesco Santoro1, Natale Daniele Brunetti1, Nicola Tarantino1
1Dipartimento di Cardiologia, Università degli Studi, Foggia.
Giornale Italiano Di Cardiologia (2006)
|November 22, 2016
Summary
Takotsubo cardiomyopathy, or stress cardiomyopathy, is a reversible heart condition with a poorer prognosis than previously believed. Its exact cause is unknown but involves stress hormones and the body's response to them.
Area of Science:
- Cardiology
- Endocrinology
- Pathophysiology
Background:
- Takotsubo cardiomyopathy (TTC), first described in 1991, is an acute, reversible cardiac failure.
- The prognosis for TTC is less favorable than initially perceived.
- The precise pathophysiology remains unclear, though elevated catecholamines are implicated.
Purpose of the Study:
- To review the diagnostic classification of stress cardiomyopathy.
- To discuss the short- and mid-term prognosis and precipitating factors.
- To explore primary and secondary forms and potential drug therapies for TTC.
Main Methods:
- This is a review article, synthesizing existing clinical and experimental studies.
- The review addresses diagnostic criteria, prognostic data, and etiological factors.
- It examines proposed pathophysiological mechanisms and therapeutic strategies.
Main Results:
- TTC involves a complex cascade, including hypothalamic-pituitary-adrenal axis activation and catecholamine surges.
- Multiple, non-exclusive pathophysiological explanations exist.
- Current understanding highlights the need for improved diagnostic tools and targeted treatments.
Conclusions:
- Further clinical and experimental research is essential for advancing the diagnosis and treatment of stress cardiomyopathy.
- A comprehensive understanding of TTC's pathophysiology is crucial for improving patient outcomes.
- Targeted therapies require further investigation and validation.
Related Concept Videos
01:25Cardiomyopathy I: Introduction and Classification
743
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
743
01:26Coronary Artery Disease II: Pathophysiology
862
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
862
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
611
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
611
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
603
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
603
01:30Cardiomyopathy II: Dilated Cardiomyopathy
698
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
698
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
706
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
706